Weight-loss Drug Developer BioAge Labs Seeks $198M in Upcoming IPO
Thursday, 26 September 2024, 08:24
Weight-loss Drug Developer BioAge Labs Targets $198M IPO
Weight-loss drug developer BioAge Labs aims to raise $198 million from its upcoming U.S. IPO. The company will be offering 11,000,000 shares priced at $18.00 each, marking a significant move in the competitive field of weight-loss solutions.
Details of the Offering
- Goal: Raise $198 million
- Shares Offered: 11,000,000
- Offer Price: $18.00 each
This IPO positions BioAge Labs to tap into the increasing demand for effective weight-loss options powered by scientific innovations.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.